CCR5 Delta 32 Deletion as a Protective Factor in Czech
First-Wave COVID-19 Subjects

J 2021

CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects

HUBACEK, Jaroslav A., Ladislav DUŠEK, Ondřej MÁJEK, Vaclav ADAMEK, Tereza CERVINKOVA et. al.

Basic information

Original name

CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects

Authors

HUBACEK, Jaroslav A. (203 Czech Republic, guarantor), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Ondřej MÁJEK (203 Czech Republic, belonging to the institution), Vaclav ADAMEK (203 Czech Republic), Tereza CERVINKOVA (203 Czech Republic), Dana DLOUHA (203 Czech Republic), Jozef PAVEL (203 Czech Republic) and Vera ADAMKOVA (203 Czech Republic)

Edition

Physiological research, Praha, Fyziologický ústav AV ČR, 2021, 0862-8408

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30105 Physiology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.139

RIV identification code

RIV/00216224:14110/21:00121769

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.33549/physiolres.934647

UT WoS

000631146600011

Keywords in English

COVID-19; CCR5; Polymorphism; Deletion; Delta 32

Abstract

V originále

Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), has spread widely around the globe. Significant inter-individual differences have been observed during the course of the infection, which suggests that genetic susceptibility may be a contributing factor. CC chemokine receptor 5 (CCR5), which acts as a co-receptor for the entry of HIV-1 into cells, is promising candidate whose can have an influence on SARS-CoV-2 infection. A genetic mutation known as CCR5 Delta 32, consisting of a 32-nucleotide deletion, encodes a truncated protein that protects homozygous carriers of the deletion from HIV-1 infection. Similarly, inhibition of CCR5 seems to be protective against COVID-19. In our study, we successfully genotyped 416 first-wave SARS-CoV-2-positive infection survivors (164 asymptomatic and 252 symptomatic) for CCR5 Delta 32, comparing them with a population based sample of 2,404 subjects. We found the highest number (P=0.03) of CCR5 Delta 32 carriers in SARS-CoV-2-positive/COVID-19-asymptomatic subjects (23.8 %) and the lowest number in SARS-CoV-2-positive/COVID-19-symptomatic patients (16.7 %), with frequency in the control population in the middle (21.0 %). We conclude that the CCR5 Delta 32 I/D polymorphism may have the potential to predict the severity of SARS-CoV-2 infection.

Citovat

HUBACEK, Jaroslav A., Ladislav DUŠEK, Ondřej MÁJEK, Vaclav ADAMEK, Tereza CERVINKOVA, Dana DLOUHA, Jozef PAVEL and Vera ADAMKOVA. CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects. Physiological research. Praha: Fyziologický ústav AV ČR, 2021, vol. 70, No 1, p. 111-115. ISSN 0862-8408. Available from: https://dx.doi.org/10.33549/physiolres.934647.

@article{1776197,
   author = {Hubacek, Jaroslav A. and Dušek, Ladislav and Májek, Ondřej and Adamek, Vaclav and Cervinkova, Tereza and Dlouha, Dana and Pavel, Jozef and Adamkova, Vera},
   article_location = {Praha},
   article_number = {1},
   doi = {http://dx.doi.org/10.33549/physiolres.934647},
   keywords = {COVID-19; CCR5; Polymorphism; Deletion; Delta 32},
   language = {eng},
   issn = {0862-8408},
   journal = {Physiological research},
   title = {CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects},
   url = {https://www.biomed.cas.cz/physiolres/pdf/2021/70_111.pdf},
   volume = {70},
   year = {2021}
}

TY  - JOUR
ID  - 1776197
AU  - Hubacek, Jaroslav A. - Dušek, Ladislav - Májek, Ondřej - Adamek, Vaclav - Cervinkova, Tereza - Dlouha, Dana - Pavel, Jozef - Adamkova, Vera
PY  - 2021
TI  - CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects
JF  - Physiological research
VL  - 70
IS  - 1
SP  - 111-115
EP  - 111-115
PB  - Fyziologický ústav AV ČR
SN  - 08628408
KW  - COVID-19
KW  - CCR5
KW  - Polymorphism
KW  - Deletion
KW  - Delta 32
UR  - https://www.biomed.cas.cz/physiolres/pdf/2021/70_111.pdf
N2  - Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), has spread widely around the globe. Significant inter-individual differences have been observed during the course of the infection, which suggests that genetic susceptibility may be a contributing factor. CC chemokine receptor 5 (CCR5), which acts as a co-receptor for the entry of HIV-1 into cells, is promising candidate whose can have an influence on SARS-CoV-2 infection. A genetic mutation known as CCR5 Delta 32, consisting of a 32-nucleotide deletion, encodes a truncated protein that protects homozygous carriers of the deletion from HIV-1 infection. Similarly, inhibition of CCR5 seems to be protective against COVID-19. In our study, we successfully genotyped 416 first-wave SARS-CoV-2-positive infection survivors (164 asymptomatic and 252 symptomatic) for CCR5 Delta 32, comparing them with a population based sample of 2,404 subjects. We found the highest number (P=0.03) of CCR5 Delta 32 carriers in SARS-CoV-2-positive/COVID-19-asymptomatic subjects (23.8 %) and the lowest number in SARS-CoV-2-positive/COVID-19-symptomatic patients (16.7 %), with frequency in the control population in the middle (21.0 %). We conclude that the CCR5 Delta 32 I/D polymorphism may have the potential to predict the severity of SARS-CoV-2 infection.
ER  -

HUBACEK, Jaroslav A., Ladislav DUŠEK, Ondřej MÁJEK, Vaclav ADAMEK, Tereza CERVINKOVA, Dana DLOUHA, Jozef PAVEL and Vera ADAMKOVA. CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects. \textit{Physiological research}. Praha: Fyziologický ústav AV ČR, 2021, vol.~70, No~1, p.~111-115. ISSN~0862-8408. Available from: https://dx.doi.org/10.33549/physiolres.934647.

Detailed Information on Publication Record